N-Acetylcysteine in Neonatal Congenital Heart Surgery (INACT Study)

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
Transposition of Great VesselsCongenital Heart Disease
Interventions
DRUG

N-acetylcysteine

"Loading dose: Subjects randomized to IV NAC will receive a total loading dose of 100 mg/kg of 10% (100 mg/mL) solution. Acetadote is supplied as a 20% solution (200 mg/mL) and will be diluted 1:1 with an equal volume of D5W. The volume of the loading dose will be 1 mL/kg, anticipated to be 2.5-5 mL in our patient population. The loading dose will be administered over 1 hr beginning 1 hr prior to the patient's OR time. Subjects in the placebo group will receive 1 mL/kg of D5W over 1 hr.~Maintenance infusion: Subjects randomized to IV NAC will receive an infusion of 10 mg/kg/hr of 10% (100 mg/mL) solution for 24 hrs, starting in the OR after weaning from CPB. Acetadote is supplied as a 20% solution (200 mg/mL) and will be diluted 1:1 with an equal volume of D5W. The volume of the maintenance infusion will be 0.1 mL/kg/hr, anticipated to be 0.25-0.5 mL/hr in our patient population. Subjects in the placebo group will receive 0.1 mL/kg/hr of D5W for 24 hrs."

DRUG

Placebo

D5W bolus prior to surgery and D5W infusion after surgery in an equal volume to the drug arm.

Trial Locations (1)

48109-0204

University of Michigan, Ann Arbor

All Listed Sponsors
lead

University of Michigan

OTHER

NCT00374088 - N-Acetylcysteine in Neonatal Congenital Heart Surgery (INACT Study) | Biotech Hunter | Biotech Hunter